Latest Clinical Development News

Immuron Limited posted a 6% rise in FY26 sales to $7.7 million, improved its net loss by $1.4 million, and secured FDA approval for IMM-529, underpinning a strategic pivot towards profitability and geographic expansion.

Percheron Therapeutics has partnered with Vanderbilt Health to initiate a clinical trial testing HMBD-002 in combination with standard treatments for high-risk acute myeloid leukaemia and myelodysplastic syndrome, targeting a recruitment start in late 2026.

LTR Pharma is shifting gears from clinical trials to commercial rollout, securing US partnerships for ROXUS and reporting encouraging SPONTAN Phase II data that supports FDA approval ambitions.

Actinogen Medical reported a $15.38 million loss for FY2026 while progressing its lead Alzheimer's drug Xanamem toward pivotal trial results expected this November. The company secured regulatory alignment and strengthened its cash position to fund operations through mid-2027.

Syntara Limited’s FY2026 results show a 7.9% revenue decline and a 13.6% increase in net loss amid significant clinical progress, including FDA backing for its lead drug amsulostat and a successful $8.8 million capital raise.

Biotron Limited posted a $1.52 million net loss for FY2026, driven by integration and R&D costs following its Sedarex acquisition, while progressing regulatory and clinical development for its SedRxTM anaesthetic and antiviral pipeline.

Acrux Limited reported a 46% revenue increase to $6.6 million in FY26, driven by US generic product royalties and licensing milestones, while narrowing its net loss by 90%. The company is pivoting towards developing a female testosterone therapy with encouraging Phase II data and active regulatory engagement.

NeuroScientific Biopharmaceuticals posted a $4.69 million loss for FY2026, driven by R&D ramp-up and clinical progress with its StemSmart™ platform, while halting independent development of its glaucoma drug EmtinB to pursue licensing deals.

Racura Oncology's FY2026 results reveal a widening loss despite a 22% revenue dip, underpinned by significant scientific progress on its lead drug targeting the elusive MYC gene and a robust $34.3 million cash position.

Neurizon Therapeutics has completed enrolment in its pivotal HEALEY ALS Platform Trial ahead of schedule, secured critical manufacturing and funding agreements, and reduced its net loss for FY2026 while preparing for topline results in late Q2 2027.

Prescient Therapeutics launches a $7 million Share Purchase Plan at an 18.8% discount to fund advancement of its PTX-100 cancer therapy beyond a key 2026 Dose Optimisation Committee review.

EMVision Medical Devices has made significant strides in its emu™ bedside scanner pivotal trial and First Responder program, boosting FY26 revenue by 57% while trimming its net loss by 15%.